Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

Rhea-AI Summary

Anavex Life Sciences (Nasdaq: AVXL) announced that President & CEO Christopher U Missling, PhD will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 11:50 AM ET.

A live audio webcast will be available via the company’s Investors section at www.anavex.com, and an archived edition will be posted later that day.

News Market Reaction – AVXL

+0.92%

10 alerts

+0.92% Session close to close

+3.0% Peak in 25 min

$434.35M Market Cap

0.1x Rel. Volume

In the Feb 25 session, AVXL gained 0.92%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.0% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Anavex’s participation in a major healthcare conference, with managemen...

Analysis

This announcement highlights Anavex’s participation in a major healthcare conference, with management presenting on March 2, 2026 at 11:50 AM (ET). It represents an investor-relations visibility event rather than a new clinical or financial milestone. In context of recent governance, earnings, and pipeline updates, investors may focus on any incremental commentary from the presentation while monitoring future regulatory, clinical, and financing disclosures for more substantive catalysts.

Key Figures

Conference edition: 46th Presentation date: March 2, 2026 Presentation time: 11:50 AM (ET) +1 more

4 metrics

Conference edition 46th TD Cowen Annual Health Care Conference

Presentation date March 2, 2026 Scheduled AVXL presentation at TD Cowen conference

Presentation time 11:50 AM (ET) Scheduled presentation time at conference

Publication date February 25, 2026 Press release announcing TD Cowen conference participation

Historical Context

5 past events · Latest: 2026-02-23 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
2026-02-23	Board appointment	Positive	+1.0%	Appointment of experienced healthcare leader to Board of Directors.
2026-02-09	Earnings & update	Positive	+6.1%	Quarterly results with detailed cash position and CNS pipeline progress.
2026-02-03	Earnings date set	Neutral	-2.9%	Announcement of date and logistics for upcoming earnings release.
2026-01-13	Pipeline collaboration	Positive	+8.2%	ACCESS-AD collaboration for blarcamesine in Alzheimer’s precision medicine effort.
2026-01-08	Senior hire	Positive	+4.2%	Appointment of Senior VP Global Head of Neurology with extensive CNS experience.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news events have generally seen positive price reactions, especially around clinical, strategic, and financial updates.

Recent Company History

Over recent months, Anavex has highlighted leadership additions, financial updates, and CNS pipeline progress. Governance and management news on 2026-02-23 and 2026-01-08 coincided with modest gains. Earnings and business updates on 2026-02-09 and the prior earnings-date announcement on 2026-02-03 framed the company’s cash position and operating spend. Participation in the ACCESS-AD initiative on 2026-01-13 aligned with a stronger positive move. Today’s conference appearance fits this pattern of ongoing visibility rather than a major new catalyst.

Key Terms

clinical-stage biopharmaceutical, central nervous system (CNS), Alzheimer's disease, Parkinson's disease, +3 more

7 terms

clinical-stage biopharmaceutical medical

"a clinical-stage biopharmaceutical company focused on developing innovative treatments"

A clinical-stage biopharmaceutical is a company that is developing medicines or biological treatments that are currently being tested in people in clinical trials to assess safety and effectiveness. For investors it signals a higher-risk, higher-reward profile: progress through human testing and regulatory milestones can sharply increase value if results are positive, while failed trials can wipe out expected future revenue — like a prototype that must prove it works before it can be sold widely.

central nervous system (CNS) medical

"and other central nervous system (CNS) disorders, today announced that"

The central nervous system (CNS) is the part of the body that includes the brain and spinal cord, acting as the control center for processing information and directing actions. It is essential for coordinating all bodily functions, from movement to thinking. For investors, understanding the CNS is important because it illustrates how complex systems—like markets or organizations—rely on core components to operate smoothly.

Alzheimer's disease medical

"focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease"

A progressive brain disorder that slowly erodes memory, thinking and the ability to carry out daily tasks as nerve cells are damaged and lost; symptoms typically worsen over years and can lead to severe impairment. Investors care because it drives a large, growing market for diagnostics, treatments and care services, but also carries high scientific, regulatory and commercial risk—similar to developing a complex new product that must pass difficult safety tests before it can reach patients.

Parkinson's disease medical

"innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia"

A progressive brain disorder in which nerve cells that produce the chemical dopamine gradually die, leading to tremors, slowness of movement, stiffness and balance problems. Think of it like the gradual wearing down of the brain’s movement-control circuitry. It matters to investors because prevalence, treatment advances, diagnostic tests, medical-device approvals and care costs shape demand and revenue prospects for drug developers, device makers and healthcare providers, and clinical trial or regulatory news can move stock prices.

schizophrenia medical

"Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative"

A chronic brain disorder that changes how a person thinks, perceives reality, feels and interacts with others, often causing hallucinations, false beliefs and trouble organizing thoughts or daily life. It matters to investors because the condition creates demand for long‑term treatments, diagnostics and support services; developing effective therapies can be costly, risky and highly regulated, but successful drugs or devices can open large, steady markets—think of it like fixing a deep, complex software bug that many users rely on.

Rett syndrome medical

"and rare diseases, including Rett syndrome, and other central nervous system"

A rare genetic disorder that disrupts normal brain development in young children, most commonly girls, leading to slowed growth, loss of purposeful hand use, repetitive hand movements, motor problems, speech loss, and cognitive and breathing irregularities. Investors watch it because its severity and few treatment options create clear medical need and potential markets for therapies; think of it as a broken traffic signal in the brain that, if fixed, could restore many downstream functions.

webcast technical

"A live audio webcast will be accessible through the Investors section"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Christopher U Missling, PhD, President & Chief Executive Officer, will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2^nd, 2026 at 11:50 AM (ET).

A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. An archived edition of the session will be available later that day.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX^®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX^®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX^®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX^®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX^®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX^®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com

FAQ

When will Anavex (AVXL) present at the TD Cowen conference in March 2026?

Anavex will present on March 2, 2026 at 11:50 AM ET. According to the company, Christopher U Missling, PhD, President & CEO, will deliver the presentation and discuss recent clinical and corporate developments.

How can investors listen to Anavex (AVXL) presentation at TD Cowen on March 2, 2026?

Investors can access a live audio webcast via the company’s Investors section at www.anavex.com. According to the company, the live stream will be available during the presentation and an archived edition will be posted later that day.

Will Anavex (AVXL) make the TD Cowen presentation available after March 2, 2026?

Yes, an archived edition will be available later the same day. According to the company, the session’s audio recording will be posted on the Investors section of www.anavex.com for later listening.

Who will present for Anavex (AVXL) at the TD Cowen 46th Annual Health Care Conference?

Christopher U Missling, PhD, President & CEO, will present on behalf of Anavex. According to the company, he will discuss the firm’s clinical-stage programs and recent corporate updates during the scheduled session.

What topics is Anavex (AVXL) likely to cover in the March 2, 2026 TD Cowen presentation?

The presentation will focus on Anavex’s clinical-stage programs in CNS disorders, including Alzheimer’s and Rett syndrome. According to the company, discussion will cover clinical development progress and corporate updates relevant to investors.

Where can I find the Anavex (AVXL) webcast link for the TD Cowen presentation on March 2, 2026?

The webcast link will be posted in the Investors section at www.anavex.com. According to the company, the live audio stream and later archived edition will be accessible there for investors and the public.